Roche Aktie News

Shares in CelLBxHealth PLC (AIM:CLBX, NSX:ANPCY) rose 10% to 2.3p after the company revealed encouraging early results from a study showing its cancer cell detection platform works seamlessly with Roche's leading diagnostic equipment. The Guildford-based biotech, which specialises in analysing circulating tumour cells, live cancer cells that move through the bloodstream, presented the findings ...

CelLBxHealth PLC (AIM:CLBX, NSX:ANPCY) has unveiled early results from a study that links its cancer cell detection technology with Roche's widely used diagnostic equipment, a step that could make blood-based cancer testing easier to integrate into hospital laboratories. The Guildford-based company, which focuses on analysing circulating tumour cells, live cancer cells that break away from tumo...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that it will showcase 46 abstracts, including 12 oral presentations, from its industry-leading hematology portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, held December 6-9, 2025 in Orlando, Florida. “The data we will present...

Basel, 3 November 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will showcase 46 abstracts, including 12 oral presentations, from its industry-leading haematology portfolio at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, held 6-9 December 2025 in Orlando, Florida, US.

BOSTON--(BUSINESS WIRE)--Manifold Bio, a platform therapeutics company pioneering AI-guided drug discovery coupled with direct-to-vivo measurement, today announced a strategic research collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY). The partnership will apply Manifold's proprietary tissue-targeting shuttle portfolio and mDesign AI-driven in vivo discovery engine to ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today statistically significant and clinically meaningful results from the Phase III ALLEGORY study of Gazyva® (obinutuzumab) in adults with systemic lupus erythematosus (SLE) on standard therapy. The study met its primary endpoint showing a higher percentage of people ac...

Basel, 3 November 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today statistically significant and clinically meaningful results from the phase III ALLEGORY study of Gazyva®/Gazyvaro® (obinutuzumab) in adults with systemic lupus erythematosus (SLE) on standard therapy. The study met its primary endpoint showing a higher percentage of people achieved a minimum four-point improvement in SL...

Roche CH0012032048 hat die Ergebnisse mit seinem Wirkstoff Gazyva/Gazyvaro (Obinutuzumab) bei Erwachsenen mit der Autoimmunerkrankung Systemischer Lupus Erythematodes (SLE) einen Behandlungserfolg erzielt.